Isabelle Borghini-Fuhrer

Review of pyronaridine anti-malarial properties and product characteristics

Simon L. Croft, Stephan Duparc, Sarah Arbe‐Barnes et al. · Malaria Journal · 2012 · 158 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial

Antoinette Tshefu, Oumar Gaye, Kassoum Kayentao et al. · The Lancet · 2010 · 143 citations

Medicine, Pediatrics, Pharmacology +15

Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial

Issaka Sagara, Abdoul Habib Béavogui, Issaka Zongo et al. · The Lancet · 2018 · 142 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +16

Pyronaridine–Artesunate versus Mefloquine plus Artesunate for Malaria

Ronnatrai Rueangweerayut, Aung Pyae Phyo, Chirapong Uthaisin et al. · New England Journal of Medicine · 2012 · 110 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Pyronaridine-Artesunate versus Chloroquine in Patients with Acute Plasmodium vivax Malaria: A Randomized, Double-Blind, Non-Inferiority Trial

Poravuth Yi, Duong Socheat, Ronnatrai Rueangweerayut et al. · PLoS ONE · 2011 · 108 citations · Full text

Medicine, Infectious Diseases, Pharmacology +14